Welcome to our dedicated page for Nektar Therapeutics SEC filings (Ticker: NKTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nektar Therapeutics (NKTR) SEC filings page brings together the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Nektar’s common stock is registered under Section 12(b) of the Exchange Act and trades on the Nasdaq Capital Market, and its filings provide structured insight into clinical progress, capital markets activity and corporate governance.
Recent Form 8-K reports include detailed descriptions of topline results from the Phase 2b REZOLVE-AD trial in atopic dermatitis and the Phase 2b REZOLVE-AA trial in alopecia areata, including study design, patient populations, primary and secondary endpoints, and summarized efficacy and safety outcomes. Other 8-K filings cover financial results for completed quarters, underwritten equity offerings under an effective shelf registration statement, and notices related to Nasdaq minimum bid price compliance.
Through these filings, investors can review how Nektar characterizes rezpegaldesleukin (REZPEG, or NKTR-358) as a first-in-class regulatory T cell stimulator and IL-2 pathway agonist, and how it describes additional pipeline programs such as NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255. Filings also outline FDA Fast Track designations for rezpegaldesleukin in atopic dermatitis and alopecia areata, as well as risk factor language and forward-looking statement disclaimers that frame development and regulatory uncertainty.
On Stock Titan, these SEC documents are updated as they are made available on EDGAR. AI-powered tools can help explain key sections of Nektar’s 8-Ks and related reports in plain language, highlight important clinical and financing disclosures, and surface items such as listing status updates and material agreements. This allows readers to quickly understand the implications of new filings for Nektar’s immunology pipeline and its Nasdaq-listed equity.
Nektar Therapeutics is a clinical-stage biopharma focused on immunotherapy for autoimmune disease and cancer. Its lead asset, rezpegaldesleukin, targets IL‑2 receptors to expand regulatory T cells and is in Phase 2b trials for atopic dermatitis and alopecia areata, with FDA Fast Track designations for both indications.
In the REZOLVE‑AD study, rezpegaldesleukin achieved statistically significant improvements in standard eczema scores and itch at 16 weeks and showed durable responses out to 52 weeks with favorable tolerability, mainly mild injection site reactions. REZOLVE‑AA topline data showed meaningful hair regrowth trends and supportive safety, with statistical significance when four ineligible patients were excluded.
The pipeline also includes preclinical TNFR2 agonist antibodies NKTR‑0165 and NKTR‑0166 for autoimmune disease, oncology candidate NKTR‑255 targeting IL‑15 in combination studies, and preclinical PEG‑CSF1 program NKTR‑422. Nektar reported research and development expense of $117,330 (in thousands) for 2025 and remains dependent on future partnerships and sufficient capital to advance its programs.
Nektar Therapeutics reported weaker 2025 results alongside a significantly stronger cash position after recent financings. Revenue for 2025 was $55.2 million compared to $98.4 million in 2024, mainly because product sales ended after the December 2024 sale of the Huntsville manufacturing facility and non-cash royalty revenue declined.
Total operating costs and expenses were $195.3 million versus $203.6 million in 2024, reflecting lower cost of goods sold and reduced R&D and G&A spending, partially offset by restructuring and impairment charges linked to San Francisco real estate and an equity-method loss from Gannet BioChem. Net loss widened to $164.1 million, or $9.73 per share, from $119.0 million, or $8.68 per share, while non-GAAP net loss excluding the equity investment loss and restructuring was $146.0 million, or $8.66 per share.
Cash and investments in marketable securities were $245.8 million as of December 31, 2025, versus $269.1 million a year earlier, and this balance excludes approximately $432 million of net proceeds from a $460 million secondary offering and $44 million of net proceeds from at-the-market share sales completed in early 2026. Management highlighted positive Phase 2 data for lead autoimmune candidate rezpegaldesleukin and plans to initiate a Phase 3 atopic dermatitis program in June 2026 while advancing additional immunology and oncology pipeline assets.
Nektar Therapeutics reports that FMR LLC beneficially owns 3,036,760.61 shares of common stock, representing 11.1% of the class as reported on
NEKTAR THERAPEUTICS Chief R&D Officer Jonathan Zalevsky sold 180 shares of common stock on February 18, 2026 to cover required tax withholding obligations tied to vesting RSUs, and this was not a discretionary trade. The weighted average sale price was $73.00 per share, and he held 21,174 shares directly after the transaction.
Nektar Therapeutics President & CEO Robin Howard W reported an open-market sale of 423 shares of common stock on February 18, 2026 at a weighted average price of $73.00 per share. According to the disclosure, these shares were sold to cover required tax withholding obligations related to vesting restricted stock units, and the filing notes this was not a discretionary trade. After the transaction, he directly held 75,489 shares of common stock, with an additional 28 shares held indirectly by his spouse.
Form 144 filing reports insider share sales and planned sales. The filing lists 423 common shares marked under "Securities To Be Sold" tied to Restricted Stock Vesting on
NKTR files a Section 144 notice to sell 180 common shares related to restricted stock vesting dated
The excerpt also records prior sales by Jonathan Zalevsky: 1,157 shares sold on
G1 Execution Services, Susquehanna Portfolio Strategies, and Susquehanna Securities filed Amendment No. 1 to a Schedule 13G reporting beneficial ownership of 809,967 shares of Nektar Therapeutics common stock, equal to 4.0% of the class.
The filing is based on 20,341,589 shares outstanding as of November 10, 2025, as disclosed in the company’s Form S-3ASR. Susquehanna Securities’ position includes options to buy 410,600 shares. The firms state the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Nektar.
Nektar Therapeutics is raising new capital through an upsized underwritten public offering of common stock and pre-funded warrants. The company agreed to sell 6,603,449 common shares at $58.00 each and 293,103 pre-funded warrants at $57.9999 each, with underwriters also exercising a 30-day option to buy an additional 1,034,482 common shares at the public price, all before underwriting discounts and commissions.
The transaction is expected to generate gross proceeds of about $400 million and is scheduled to close on February 13, 2026, subject to customary conditions. Nektar plans to use the net proceeds for general corporate purposes, including research and development, Phase 3 trials for rezpegaldesleukin, clinical development, and manufacturing costs to advance its drug pipeline.
Nektar Therapeutics is offering 6,603,449 shares of common stock and pre-funded warrants to purchase up to 293,103 shares, at $58.00 per share (or $57.9999 per pre-funded warrant), for estimated net proceeds of about $375.6 million, or $432.0 million if the underwriters fully exercise their option for 1,034,482 additional shares.
The company plans to use the cash, together with existing funds, for general corporate purposes, including research, clinical development and manufacturing, notably Phase 3 trials for its autoimmune drug candidate rezpegaldesleukin. Nektar reported preliminary cash and marketable securities of approximately $229.1 million as of January 31, 2026.
Recent Phase 2b REZOLVE‑AD data in atopic dermatitis showed sustained efficacy through 52 weeks and a well‑tolerated safety profile, and Nektar has aligned with the FDA on two Phase 3 registrational trials starting in the second quarter of 2026. The company highlights significant dilution to new investors versus its September 30, 2025 net tangible book value per share.